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Purpose: The aim of this study was to find an optimal range of activated clotting 
time (ACT) during off-pump coronary artery bypass surgery (OPCAB) yielding 
ischemic protection without the risk of hemorrhagic complications in patients with 
recent exposure to dual antiplatelet therapy. Materials and Methods: Three hun-
dred and five patients who received aspirin and clopidogrel within 7 days of isolat-
ed multi-vessel OPCAB were retrospectively studied. Combined hemorrhagic and 
ischemic outcome was defined as the occurrence of 1 of the following: significant 
perioperative bleeding (>30% of estimated blood volume), transfusion of packed 
red blood cell (pRBC) ≥2 U, or myocardial infarction (MI). This was compared in 
relation to the tertile distribution of the time-weighted average ACT-212-291 sec 
(first tertile), 292-334 sec (second tertile), 335-485 sec (third tertile). Results: The 
amount of perioperative blood loss was 937±313 mL, 1014±340 mL, and 1076± 
383 mL, respectively (p=0.022). Significantly more patients in the third tertile de-
veloped MI (4%, 4%, and 12%, respectively, p=0.034). The incidence of signifi-
cant perioperative blood loss and transfusion of pRBC ≥2 U were lower in the first 
tertile than those of other tertiles without statistical significance. In the multivariate 
analysis, the first tertile was associated with a 52% risk reduction of combined 
hemorrhagic and ischemic outcomes (95% confidence interval: 0.25-0.92, p= 
0.027). Conclusion: A lower degree of anticoagulation with a reduced initial hepa-
rin loading dose should be carefully considered for patients undergoing OPCAB 
who have recently been exposed to clopidogrel.
Key Words:   Clopidogrel, heparin, time weighted average activated clotting time, 
off-pump coronary artery bypass surgery
INTRODUCTION
In the context of surgical revascularization, off-pump coronary artery bypass sur-
gery (OPCAB) is gaining renewed appreciation as studies report improved out-
come in high-risk patients compared with the on-pump procedure.1,2 Despite 
avoiding cardiopulmonary bypass (CPB), OPCAB still requires systemic heparin-
ization due to the obligatory period of coronary hemostasis during grafting. In ad-
dition, concerns have been raised regarding a hypercoagulable state associated 
Young Song, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 5   September 20131120
emergent conversion to on-pump coronary artery bypass 
grafting (CABG), or excessive postoperative bleeding due 
to any obvious surgical bleeder. 
All patients received standardized anesthetic and surgical 
care. General anesthesia was induced with intravenous mid-
azolam and sufentanil. Anesthesia was maintained with sevo-
flurane and continuous infusion of sufentanil. Neuromuscu-
lar blockade was achieved by administering rocuronium 
bromide and maintained with continuous infusion of ve-
curonium bromide. Intravascular volume replacement was 
managed with crystalloid and colloid solutions to maintain the 
pulmonary capillary wedge pressure as measured by pulmo-
nary arterial catheter (Swan-Ganz CCombo CCO/SvO2; Ed-
wards Lifesciences, Irvine, CA, USA) between 8-16 mm Hg 
according to the baseline values. Pulmonary arterial blood 
temperature was maintained at 36-37°C with a warm mat-
tress, forced warm air blanket and fluid warmer as neces-
sary. All surgical procedures were performed through a me-
dian sternotomy. The heart was displaced with a deep 
pericardial traction sutures, large gauze (12×70 cm), and a tis-
sue stabilizer (Octopus Tissue stabilization System; Medtron-
ic Inc., Minneapolis, MN, USA). Revascularization was 
carried out using a left internal mammary artery connected 
with an additional graft using radial artery, great saphenous 
vein, or both in a Y-configuration. All patients were trans-
ferred to the intensive care unit after the operation, and 
standardized protocol for immediate postoperative care was 
followed. Aspirin (100 mg) and clopidogrel (75 mg) were 
given orally starting from 24 hr after the surgery, and sup-
plemental 100 mg of cilostazol was added for the patients 
whose vein was grafted or arterial conduit was calcified in a 
measure.
Heparinization and ACT measurements during 
anastomoses 
Baseline ACT was determined immediately before the in-
duction of anesthesia. In the preference and discretion of 
the surgeon and attending anesthesiologist, initial 80-150 
U/kg dose of unfractionated heparin was given to achieve a 
target ACT of 200, 250, or >300 sec just prior to Y graft for-
mation. Five min after the initial dose of heparin, the ACT 
was measured and follow-up measurements during graft 
anastomoses were performed every 30 min as long as it re-
mained within the target range. Otherwise, 1000-2000 U of 
additional heparin was given according to the remaining 
number of distal anastomoses, and ACT was re-measured 
after 5 min. At the end of the anastomoses, the ACT was 
with surgery-related systemic inflammatory response and 
warm regional myocardial ischemia/reperfusion, jeopardiz-
ing the early graft patency.3-5 Accordingly, an aggressive an-
ticoagulation strategy maintaining a target activated clotting 
time (ACT) of >300 s has been advocated.6,7
Due to the conflicting demands of prevention from isch-
emic and hemorrhagic complications,8,9 it is crucial to de-
fine the optimal level of anticoagulation with heparin dur-
ing OPCAB. Contrary to surgical revascularization using 
CPB, a generally accepted uniform anticoagulation strategy 
for OPCAB is currently lacking. Surveys of different coun-
tries report achievement of systemic anticoagulation using 
heparin to maintain a target ACT from 200 s to even >480 s 
requiring full heparinization during OPCAB.10,11
In the era of dual antiplatelet therapy, many patients pres-
ent to surgery with continued clopidogrel therapy because 
of its ischemic benefit.12-14 Although OPCAB has been safe-
ly performed in these patients,15-17 clopidogrel therapy in 
proximity to surgery carries a considerable risk of hemor-
rhagic complications.18,19 Thus, it is reasonable to assume 
that these patients may benefit from a lower target range of 
ACT without being exposed to an increased risk of ischemic 
complications; however, no comprehensive studies exist.
The aim of this retrospective study is to assess an opti-
mum target range of ACT yielding ischemic protection 
without the increased risk of hemorrhagic complications in 
patients on continued dual antiplatelet therapy within 7 days 
of OPCAB. 
MATERIALS AND METHODS
　　　
Patients and perioperative management
After obtaining Institutional Review Board approval, we re-
viewed electronic medical charts of 867 patients who under-
went isolated multi-vessel OPCAB between April 2007 and 
May 2011. Patients who had received oral aspirin and clopi-
dogrel within 7 days of operation were selected. The daily 
dose of clopidogrel was 75 mg in all patients, and a single 
300 mg loading dose was administered in patients with un-
stable angina upon coronary angiography before starting the 
daily dose. Exclusion criteria included any emergency sur-
gery, history of previous cardiac surgery, myocardial infarc-
tion (MI) within 1 week from surgery, known preoperative 
coagulopathy, preoperative intravenous heparinization, use 
of any other antiplatelet or anticoagulant agents, history of 
chronic renal failure/previous renal transplantation surgery, 
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n=time interval number; 
N=total number of time intervals; 
c=ACT measured at each end of time interval (sec) 
Endpoints
The primary end point of the current study was to compare 
combined hemorrhagic and ischemic outcomes in relation 
to the tertile distribution of TWA ACT. The hemorrhagic out-
come endpoint included the incidence of significant blood 
loss and transfusion of two or more units of pRBC during the 
perioperative (intraoperative and postoperative 24 hr) peri-
od. We defined the significant blood loss as profuse bleed-
ing of more than 30% of the estimated blood volume. The 
ischemic outcome endpoint was MI occurring within post-
operative 7 days. MI was defined as the occurrence of in-
crease in creatine kinase-MB (five times above the upper 
normal limit) and/or development of new pathologic Q 
wave on electrocardiogram.20 CK-MB was evaluated 1 day 
prior to surgery and daily for 1 week after surgery. Second-
ary endpoints included evaluation of the risk factors for 
composite of hemorrhagic and ischemic outcome endpoints 
including the TWA ACT tertile. The predictive role of TWA 
ACT tertile on the each individual endpoint was also inves-
tigated.
Additionally, thirty-day angiographic patency of bypass 
grafts was compared among the tertiles. It was determined 
by reviewing computed tomography (CT) angiogram find-
ings, which were performed using a 16-slice CT scanner 
(Sensation 16, Siemens, Forchheim, Germany) with 100 mL 
to 120 mL of nonionic contrast agents (370 mg/mL iodine, 
Iopamiro; Bracco, Milano, Italy) at our institution. The graft 
was defined as occluded if a stump was seen or if there was 
no contrast in a grafted area known by operative report.
 
Statistical analysis 
Statistical analyses were performed using SPSS 18.0 (SPSS 
Inc., Chicago, IL, USA). Continuous variables among the 
tertiles were compared by one-way analysis of variance with 
a Bonferroni post-hoc test. Continuous variables were com-
pared between patients who were transfused or not by t-test 
for normally distributed values; otherwise, Mann-Whitney 
U tests were used. Proportions were compared by Fisher 
exact test or chi-square test as appropriate. The odds ratios 
and 95% confidence intervals (CI) investigating the inde-
pendent predictive role of TWA ACT on the hemorrhagic 
and ischemic endpoints were assessed by logistic regres-
sion. Variables with p<0.2 between patients who were asso-
measured again and heparin activity was neutralized with 
20-50 mg of intravenous protamine sulfate to achieve the 
baseline ACT. A follow-up measurement of ACT was per-
formed after 10 min. ACTs were measured by blood sam-
pling from an arterial line, with a standardized Hemochrone 
device (International Technidyne Corp, Edison, NJ, USA) 
using Hemochron HRFTCA510 celite ACT tubes. Admin-
istration of heparin and protamine, measured ACT levels, 
and time intervals between the measurements were pro-
spectively recorded to an institutional database.
 
Blood loss and transfusion management
In all cases, intraoperative blood loss was recorded as the 
amount of blood collected by a cell salvage device, which 
was processed and re-infused to the patients. Postoperative 
blood loss was recorded as the volume of chest and medias-
tinal tube drainage up to 24 h after the operation. Drained 
blood was not re-infused into patients. Allogeneic packed 
red blood cells (pRBC) were transfused when the hemato-
crit level was <24% throughout the study period. Fresh fro-
zen plasma (FFP) was transfused when the postoperative 
international normalized ratio was >1.5 with excessive 
bleeding of >200 mL/h for 2 consecutive hours. The criteria 
for the transfusion of platelets were postoperative platelet 
count <50000/mm3 with excessive bleeding >200 mL/h for 
two consecutive hours. The total number of units of pRBC, 
FFP and platelets concentrates given during the operation 
and the postoperative period were recorded. Surgical re-ex-
ploration was indicated when chest tube drainage was 
greater than 200 mL/h for 6 consecutive hours or greater 
than 400 mL during the first hour despite normalized ACT 
and global coagulation status. All data regarding blood loss 
and transfusion requirement were also prospectively re-
corded to an institutional database.
 
Outcome analyses
Time weighted average ACT
We calculated time weighted average (TWA) ACT level as 
area under the curve for the duration of the ACT measurements 
divided by duration, according to the following equation. 
Where TWA=time weighted average ACT (sec); 
△t=time interval between each measurement (min); 
TWA=
N
∑
n=1
(△tncn-1+cn)2
N
∑
n=1
(△tn )
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levels (Table 1). Intraoperative characteristics of the tertiles 
were also comparable except for ACT values and dose of 
weight-adjusted heparin and protamine administered, as ex-
pected. Total heparin doses were 100±30 U/kg, 123±50 U/
kg, and 139±37 U/kg, respectively (p<0.001) (Table 2). The 
overall percentage of patients who achieved target ACT 
levels by the first heparin dose was 93%, and 25% of pa-
tients needed extra heparin during the whole grafting peri-
od. This was distributed similarly among the tertiles. 
The amount of perioperative blood loss was 937±313 mL, 
1014±340 mL, and 1076±383 mL, respectively (p=0.022). 
The incidences of significant perioperative blood loss and 
transfusion of pRBC ≥2 U were lower in the first tertile 
compared to the other tertiles, but without statistical signifi-
cance. A significantly greater number of patients in the third 
tertile developed postoperative MI compared with those in 
the first and second tertiles (p=0.034). The composite of 
ciated with the outcome endpoint or not were first evaluat-
ed in the univariate model. Only variables with p<0.1 were 
then entered into the final model of the multivariable logis-
tic regression analysis. Categorical variables are expressed 
as the number of patients (%) and continuous variables are 
expressed as mean±standard deviation. 
 A p<0.05 was considered significant. 
 
RESULTS
 
Three hundred and five patients were enrolled in this study. 
The overall mean TWA ACT was 320±56 sec, and the me-
dian value was 311 sec. The ranges of TWA ACT levels ac-
cording to the tertile distribution were 212 to 291 sec, 292 
to 334 sec, and 335 to 485 sec. Patient characteristics were 
similar in relation to tertile distribution of the TWA ACT 
Table 1. Baseline Characteristics According to Time Weighted Average ACT during Grafting
Variables
TWA ACT (n=305)
p valueFirst tertile 
(212-291 sec) 
n=101
Second tertile 
(292-334 sec) 
n=102
Third tertile 
(335-485 sec) 
n=102
Age (yrs) 66±7 65±9 65±9 0.571
Female gender 22 (22) 24 (24) 26 (26) 0.824
Body mass index (kg/m2) 24.1±2.8 24.6±3.1 24.6±2.6 0.293
Hypertension 68 (67) 73 (72) 69 (68) 0.767
Diabetes 36 (36) 34 (33) 40 (40) 0.678
Prior cerebrovascular accident 8 (8) 10 (10) 11 (11) 0.779
Current smoker 47 (47) 48 (47) 45 (44) 0.939
Unstable angina 24 (24) 22 (22) 21 (21) 0.844
MI within 1 month before surgery 4 (4) 4 (4) 4 (4) 0.443
Previous percutaneous intervention 18 (18) 15 (15) 21 (21) 0.545
No. of diseased vessels (1/2/3) 4 (4)/15 (15)/82 (81) 3 (3)/14 (14)/85 (83) 2 (2)/19 (19)/81 (79) 0.871
Left main stenosis >50% 23 (23) 29 (29) 23 (23) 0.557
LVEF (%)   58±15   60±11 58±13 0.273
Preoperative medication
    β-blockers 67 (67) 60 (59) 57 (56) 0.292
    RAS blocker 50 (50) 58 (57) 56 (55) 0.553
    Calcium channel blockers 54 (54) 55 (54) 48 (47) 0.549
    Clopidogrel within 5 days 95 (94) 97 (95) 95 (93) 0.838
    Clopidogrel within 2 days 54 (54) 61 (60) 61 (60) 0.573
Preoperative laboratory data
    Hematocrit (%) 39±5 39±5 39±4 0.368
    Platelet count (103/mm3) 239±57 247±74 230±56 0.166
    Prothrombin time (sec) 10.8±1.6 10.9±0.7 10.7±1.6 0.562
    aPTT (sec) 30.9±6.7 31.0±8.9 32.4±8.8 0.345
    Antithrombin III (%)   92.4±16.0   96.7±36.8   96.1±13.9 0.479
TWA ACT, time-weighted average activated clotting time; MI, myocardial infarction; LVEF, left ventricular ejection fraction; RAS blocker, rennin-angiotensin 
system blocker; aPTT, activated partial thromboplastin time.
Values are the mean±SD or number of patients (%). 
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246 patients (90%, 76%, and 75% in each tertile, respec-
tively). The remainder did not undergo CT for various rea-
sons such as follow-up loss, cost, or the patient refusal. The 
incidence of impaired graft patency was comparable (8%, 
14%, and 8%, respectively, p=0.294).
DISCUSSION
The current study demonstrated that a lower degree of anti-
coagulation, represented by the first tertile of TWA ACT 
(212-291 sec) may provide net clinical benefit of hemor-
rhagic and ischemic outcomes following OPCAB in pa-
tients with recent exposure to clopidogrel, compared with 
those in the higher tertiles. The first tertile of TWA ACT 
was associated with 77% risk reduction of significant peri-
significant blood loss, transfusion of pRBC ≥2 U, or post-
operative MI occurred in 20%, 28%, and 30% of the pa-
tients for each tertile, respectively (p=0.190) (Table 3). 
In the univariate analysis of predictors for adverse com-
bined hemorrhagic and ischemic outcomes (a composite of 
significant perioperative blood loss, transfusion of pRBC 
≥2 U, or postoperative MI), age, female gender, body mass 
index (BMI), preoperative hematocrit level and platelet 
count, TWA ACT tertile, the number of grafts, and the oper-
ation time had a p<0.1. In the multivariate analysis, female 
gender, lower BMI, lower level of hematocrit, TWA ACT 
tertile, and longer operation time remained independent risk 
factors. The first tertile was associated with a 52% risk re-
duction of combined hemorrhagic and ischemic outcomes 
(95% CI: 0.25-0.92, p=0.027) (Table 4). 
Thirty-day follow-up CT angiograms were available in 
Table 2. Intraoperative Data According to Time Weighted Average ACT during Grafting
Variables
TWA ACT (n=305)
p valueFirst tertile 
(212-291 sec) 
n=101
Second tertile 
(292-334 sec) 
n=102
Third tertile 
(335-485 sec) 
n=102
Initial heparin (U/kg)   91±16 110±29  130±26 <0.001
Total heparin (U/kg) 100±30 123±50  139±37 <0.001
Initial ACT (sec) 141±18 144±18  144±17 0.390
Highest ACT (sec) 304±38 362±41  449±80 <0.001
Lowest ACT (sec) 232±24 265±24  308±48 <0.001
Total protamine (mg) 27.1±9.3   35.0±10.8    44.4±11.0 <0.001
ACT at the end of surgery (sec) 146±19 143±14  145±13 0.518
Number of grafts   3.2±0.7   3.2±0.8    3.1±0.7 0.401
Operation time (min) 246±42 250±44  246±53 0.743
Total fluid (mL) 3256±811 3265±835  3009±824 0.131
TWA ACT, time-weighted average activated clotting time.
Values are the mean±SD. 
Table 3. Hemorrhagic and Ischemic Outcomes According to Time Weighted Average ACT during Grafting
Variables
TWA ACT (n=305)
p valueFirst tertile 
(212-291 sec) 
n=101
Second tertile 
(292-334 sec) 
n=102
Third tertile 
(335-485 sec) 
n=102
Perioperative hemorrhagic outcomes
    Blood loss (mL) 937±313 1014±340 1076±383 0.022
    Significant blood loss (>30% of EBV) 7 (7) 18 (18) 16 (17) 0.063
    Transfusion of RBC ≥2 U 12 (12) 20 (20) 23 (23) 0.125
    Transfusion of FFP 15 (17) 21 (23) 15 (17) 0.420
Postoperative MI within 7 days 4 (4) 4 (4) 12 (12) 0.034
Combined incidence of significant blood 
  loss, transfusion of pRBC ≥2 U, or MI 
20 (20) 29 (28) 31 (30) 0.190
TWA ACT, time-weighted average activated clotting time; perioperative, intraoperative period combined with the postoperative period for 24 hr; EBV, esti-
mated blood volume; pRBC, packed red blood cells; FFP, fresh frozen plasma; MI, myocardial infarction.
Values are the mean±SD or number of patients (%). 
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tions is of critical importance. Yet, the clinical effect of the 
anticoagulation levels on the outcomes following OPCAB 
in such patient populations has not been addressed. Numer-
ous studies reported the impact of the degree of hepariniza-
tion on clinical outcomes in the setting of percutaneous cor-
onary intervention (PCI), during which antiplatelet agents 
are loaded.29-34 
In the current study, a lower degree of anticoagulation 
during OPCAB (TWA ACT <290 sec) was associated with 
a reduction in significant perioperative bleeding without in-
creasing postoperative MI in the patients with recent expo-
sure to clopidogrel. This is in agreement with the finding of 
the Precursor to EPILOG (PROLOG) study that demon-
strated a diminished risk of bleeding without compromising 
the peri-PCI ischemic outcomes, by reducing the heparin 
dosing for patients treated with platelet glycoprotein IIb/IIIa 
inhibitors.35 
In contrast to the PCI setting, during which anticoagula-
tion is obtained with one-off bolus of heparin, repeated ad-
ministration of heparin to maintain the target ACT for multi-
vessel OPCAB is common. We, therefore, evaluated the 
effect of anticoagulation on the outcomes in terms of TWA 
ACT that contain an element of time rather than a simple 
heparin dose. A significantly reduced risk of perioperative 
bleeding in the first tertile of TWA ACT is due, in part, to a 
smaller dose of total heparin compared to the higher ter-
tiles. A total heparin dose should be greatly influenced by 
initial heparin administered to achieve target ACT. The ac-
tual initial doses given to achieve a target of >250 sec and 
>300 sec were 100±5 and 149±6 U/kg, respectively. On the 
contrary, the initial dose administered in the first tertile of 
TWA ACT was 91±16 U/kg, while overall 88% of the total 
operative blood loss. Moreover, for composite blood loss, 
pRBC transfusion ≥2 U, postoperative MI, and the first ter-
tile of TWA ACT was associated with a 52% reduced risk. 
As dual antiplatelet therapy has become the cornerstone 
of the management strategies for coronary artery disease, 
an increasing number of patients referred for surgical revas-
cularization are brought to surgery with recent exposure to 
clopidogrel for the ischemic benefit.13 Despite concerns for 
consequent excess of hemorrhagic complications, several re-
ports have suggested that platelet inhibition, to a certain ex-
tent, may improve postoperative outcomes.12,14 OPCAB has 
been especially proposed as a safe surgical technique that can 
be performed without increasing the risk of bleeding in pa-
tients under a sustained influence of clopidogrel.15-17 On the 
contrary, concerns have been raised about the procoagulant 
activity associated with OPCAB that increases the risk of ve-
nous thrombosis and potentially endangers the patency of 
coronary anastomoses.21-25 These aspects have led to the use 
of an aggressive perioperative anticoagulation strategies in-
corporating systemic heparinization to maintain a target ACT 
of >300 s during surgery with early-resumed postoperative 
dual antiplatelet therapy.26,27 While a uniform standardized 
heparinization protocol is lacking for OPCAB, a European 
survey revealed that 41% of surgeons consider the lower lim-
it of the target ACT >300 s and 16% of surgeons even con-
sider full heparinization despite avoiding CPB.28
In patients with a recent exposure to dual antiplatelet 
therapy to OPCAB, maintaining a target ACT of >300 s 
may put patients at an unnecessary risk of periprocedural 
bleeding without the added ischemic benefit. Thus, optimal 
intraoperative anticoagulation that can minimize the proco-
agulant activity while avoiding the hemostatic deteriora-
Table 4. Risk Factors for Combined Hemorrhagic and Ischemic Endpoints 
Predictors
Univariate analysis Multivariate analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age 1.05 (1.02-1.09) 0.005 1.03 (0.99-1.08) 0.121
Female gender 4.61 (2.60-8.16) <0.001 3.24 (1.59-6.58) 0.001
Body mass index 0.83 (0.75-0.91) <0.001 0.83 (0.74-0.93) 0.001
Pre-operative Hct 0.86 (0.81-0.92) <0.001 0.92 (0.86-0.99) 0.018
Pre-operative platelet 1.00 (1.00-1.01) 0.087 1.00 (1.00-1.01) 0.666
TWA ACT during grafting
    First tertile (212-291 sec) 0.60 (0.34-1.07) 0.085 0.48 (0.25-0.92) 0.027
    Second tertile (292-334 sec) 1.11 (0.65-1.90) 0.693
    Third tertile (335-485 sec) 1.44 (0.84-2.46) 0.183
Graft number 1.69 (1.17-2.45) 0.005 1.39 (0.86-2.23) 0.176
Operation time 1.01 (1.00-1.01) 0.005 1.01 (1.00-1.02) 0.034
CI, confidence interval; TWA ACT, time-weighted average activated clotting time.
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As cumulating evidence supports its beneficial role in the 
PCI setting, further clinical experience and research regard-
ing the optimal intraoperative anticoagulation management 
in patients treated by ticagrelor are warranted. 
The current study suggests that for the patients with re-
cent exposure to clopidogrel, a lower degree of anticoagu-
lation during multi-vessel OPCAB appears to be beneficial 
in terms of surgery related ischemic and hemorrhagic com-
plications. Based on this analysis, decreased initial heparin 
dosing targeting a lower ACT, just greater than 200 sec, 
should be considered for this subset of patients. Additional 
prospective randomized controlled trials are needed to es-
tablish the optimal anticoagulation management during 
OPCAB in an era of aggressive dual-antiplatelet treatment.
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